GC tissues; normal tissues; paracancerous tissue samples; HP-negative GC tissues; HP-positive GC tissues; xenograft tumor tissues; lung tissues; blood samples
GES-1; BGC-823; BGC-823/DDP
cell line-derived xenograft
ceRNA regulation (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); chemoresistance (promotes); drug resistance (promotes)
RT-qPCR; RNA-seq; RNase R Treatment; Actinomycin D / DRB Stability Assay; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Luciferase Reporter Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Bioinformatics Analysis
circ_0046854 is highly expressed in GC tissues, especially HP-positive GC tissues, and the circ_0046854/miR-511-3p/CSF1 axis may serve as a potential therapeutic target for HP-associated GC.
In this study, circ_0046854 is a human ANKRD12-derived circRNA up-regulated in gastric cancer, especially HP-positive gastric cancer. Helicobacter pylori induces circ_0046854 through CagA, and circ_0046854 promotes GC cell growth, invasion, migration, anti-apoptosis, tumor growth, and cisplatin/DDP resistance by sponging miR-511-3p and regulating CSF1. Silencing circ_0046854 suppresses tumor growth and enhances the anti-tumor effect of DDP, suggesting the circ_0046854/miR-511-3p/CSF1 axis as a potential therapeutic target for HP-associated GC.
0.8571
Helicobacter pylori induce circ_0046854 to regulate microRNA-511-3p/CSF1 axis and enhance the resistance of gastric cancer to cisplatin.
combined biological and clinical study